Intranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency: effects on growth hormone secretion and growth
Hummelink R, Sippell WG, Benoit KG, et al. (1993). Acta Paediatrica.
Summary
A six-month pilot of the peptide given as a nasal insufflation to eight short prepubertal children. Growth hormone peaks followed the first administrations, but the response weakened after six weeks and further by six months; three children developed antibodies to GHRH that had been absent at the start. Short-term growth rate measured by knemometry rose initially then fell back, and six-month height velocity did not increase. Most children reported sneezing, runny nose or mild burning, and treatment was stopped early in two. The authors conclude the nasal form as tested is not suitable for children.